High-Grade Serous Ovarian Cancer Symptoms, Treatment & Care
What Is High-Grade Serous Ovarian Cancer?
High-grade serous ovarian cancer (HGSOC) is the most aggressive and common subtype of ovarian cancer, accounting for over 70% of cases and deaths from the disease. Unlike the less aggressive low-grade serous tumors or other epithelial types, HGSOC exhibits rapid growth due to specific molecular subtypes, such as mesenchymal and proliferative. It is characterized by frequent TP53 mutations and deficiencies in homologous recombination. This high genomic instability often leads to an advanced stage at the time of diagnosis, distinguishing HGSOC from other forms of ovarian cancer.
Symptoms and Signs of High-Grade Serous Ovarian Cancer
Common symptoms of HGSOC include persistent bloating, pelvic or abdominal pain, a feeling of fullness after eating small amounts, and frequent urination. Additional signs may include unexplained weight loss, fatigue, back pain, indigestion, and changes in bowel habits, such as constipation. These symptoms often appear during advanced stages and can mimic gastrointestinal issues, which can delay diagnosis.
Causes and Risk Factors
The primary risk factors for HGSOC are inherited BRCA1 or BRCA2 mutations, which increase the lifetime risk of developing ovarian cancer to 44% for BRCA1 carriers and 17% for BRCA2 carriers. Other risk factors include being over the age of 50, obesity, smoking (especially for mucinous types), and a family history of the disease. The exact causes involve interactions between genetic and environmental factors. Protective factors include the use of oral contraceptives, pregnancy, and breastfeeding.
Diagnosis and Staging
Diagnosis typically begins with elevated CA-125 blood tests, along with transvaginal ultrasounds and CT/MRI scans to detect pelvic masses. A surgical biopsy is needed to confirm the histology of HGSOC. Staging is conducted using the FIGO or AJCC systems, determined through peritoneal washings and lymph node sampling during cytoreductive surgery. While early detection through multimodal screening can improve outcomes, no routine screening test currently exists; high specificity (over 99.7%) is essential because of the disease's low prevalence.
Treatment Options for High-Grade Serous Ovarian Cancer
Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.
The standard first-line treatment involves debulking surgery combined with platinum-paclitaxel chemotherapy, aiming for no residual disease. For patients with BRCA mutations or homologous recombination deficiencies, maintenance therapy with PARP inhibitors like olaparib or niraparib can extend progression-free survival. Emerging treatment options include immunotherapy, anti-angiogenics such as bevacizumab, and subtype-specific clinical trials.
Prognosis and Survival Rates
*Understanding Survival Rates** The 5-year survival rate for localized HGSOC exceeds 90%. However, for advanced stages, it drops to between 30% and 50% due to early metastasis and the likelihood of recurrence. Unlike hormone-receptor-positive breast cancers, HGSOC lacks targeted markers beyond homologous recombination deficiency, leading to poorer outcomes despite aggressive treatment.
*Factors Influencing Prognosis** Factors that strongly predict better survival include optimal debulking (no residual disease), platinum sensitivity, BRCA status, and performance status. Younger patients (under 65), early-stage diagnosis, and the mesenchymal subtype may have a worse prognosis, while homologous recombination deficiency allows for benefits from PARP inhibitors.
Why Choose Everhope for HGSOC Care
Everhope Oncology combines precision oncology with functional nutrition and intravenous therapies specifically for HGSOC patients. Our multidisciplinary teams offer molecular profiling, PARP-targeted regimens, and nutrition programs to enhance quality of life and treatment response.
HGSOC Frequently Asked Questions
Common questions regarding High-Grade Serous Ovarian Cancer causes, staging, and survival.
Primarily BRCA mutations and genetic factors, with age and obesity being additional risks.
Staging is conducted using the FIGO system post-surgery, ranging from stage I (ovary-confined) to stage IV (distant spread).
Screening with CA-125 and ultrasounds can help high-risk groups, but there is a lack of broad efficacy.
Complete surgery, PARP maintenance for homologous recombination-deficient tumors, and nutritional support can enhance survival outcomes.